Significance of numbers of metastatic and removed lymph nodes in FIGO stage IB1 to IIA cervical cancer: Primary surgical treatment versus neoadjuvant chemotherapy before surgery. 2011

Hee Seung Kim, and Ji Hyun Kim, and Hyun Hoon Chung, and Hak Jae Kim, and Yong Beom Kim, and Jae Weon Kim, and Noh Hyun Park, and Yong Sang Song, and Soon-Beom Kang
Department of Obstetrics and Gynecology, Seoul National University College of Medicine, 28 Yeongeon-Dong, Jongno-Gu, Seoul, Republic of Korea.

OBJECTIVE.: The objective of this study was to compare the significance of numbers of metastatic (MLN) and removed lymph nodes (RLN) between primary surgical treatment (PST) and neoadjuvant chemotherapy followed by surgery (NCS) in patients with FIGO stage IB1 to IIA cervical cancer. METHODS.: Among 1124 patients with cervical cancer, PST (n=451) and NCS (n=73) groups were enrolled for evaluating the association between numbers of MLN and RLN, and clinical outcomes including the pattern of recurrence and survival according to the 2 treatments. RESULTS.: Mean values of progression-free survival (PFS) were 100.8 vs. 87.6 vs. 57.7 months in 0 vs. 1-2 vs. ≥3 MLN, suggesting that ≥3 MLN was associated with poor PFS (adjusted HR, 2.71; 95% CI, 1.02 to 7.21). However, there was no association between the number of MLN and survival in NCS group. The increased number of MLN was also associated with the increase of distant metastasis in PST group (44.0% vs. 72.7% vs. 78.6%; p=0.02), whereas there was no association between the number of MLN and the pattern of recurrence in NCS group. Moreover, mean values of PFS were 57.2 (<20 RLN) vs. 77.9 months (≥20 RLN) in PST group with lymph node metastasis (p=0.04), demonstrating that ≥20 RLN improved PFS in PST group (adjusted HR, 0.48; 95% CI, 0.25 to 0.95). CONCLUSIONS.: The increased number of MLN may be more significant for predicting poor survival and distant metastasis, and the increased number of RLN may be associated with better survival in the patients treated with PST than those treated with NCS.

UI MeSH Term Description Entries
D008197 Lymph Node Excision Surgical excision of one or more lymph nodes. Its most common use is in cancer surgery. (From Dorland, 28th ed, p966) Lymph Node Dissection,Lymphadenectomy,Dissection, Lymph Node,Dissections, Lymph Node,Excision, Lymph Node,Excisions, Lymph Node,Lymph Node Dissections,Lymph Node Excisions,Lymphadenectomies,Node Dissection, Lymph,Node Dissections, Lymph
D008198 Lymph Nodes They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system. Lymph Node,Node, Lymph,Nodes, Lymph
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D002583 Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX. Cancer of Cervix,Cancer of the Cervix,Cancer of the Uterine Cervix,Cervical Cancer,Cervical Neoplasms,Cervix Cancer,Cervix Neoplasms,Neoplasms, Cervical,Neoplasms, Cervix,Uterine Cervical Cancer,Cancer, Cervical,Cancer, Cervix,Cancer, Uterine Cervical,Cervical Cancer, Uterine,Cervical Cancers,Cervical Neoplasm,Cervical Neoplasm, Uterine,Cervix Neoplasm,Neoplasm, Cervix,Neoplasm, Uterine Cervical,Uterine Cervical Cancers,Uterine Cervical Neoplasm
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy

Related Publications

Hee Seung Kim, and Ji Hyun Kim, and Hyun Hoon Chung, and Hak Jae Kim, and Yong Beom Kim, and Jae Weon Kim, and Noh Hyun Park, and Yong Sang Song, and Soon-Beom Kang
January 2020, Journal of minimally invasive gynecology,
Hee Seung Kim, and Ji Hyun Kim, and Hyun Hoon Chung, and Hak Jae Kim, and Yong Beom Kim, and Jae Weon Kim, and Noh Hyun Park, and Yong Sang Song, and Soon-Beom Kang
December 2008, Gynecologic oncology,
Hee Seung Kim, and Ji Hyun Kim, and Hyun Hoon Chung, and Hak Jae Kim, and Yong Beom Kim, and Jae Weon Kim, and Noh Hyun Park, and Yong Sang Song, and Soon-Beom Kang
June 2011, Fertility and sterility,
Hee Seung Kim, and Ji Hyun Kim, and Hyun Hoon Chung, and Hak Jae Kim, and Yong Beom Kim, and Jae Weon Kim, and Noh Hyun Park, and Yong Sang Song, and Soon-Beom Kang
September 2003, Gynecologic oncology,
Hee Seung Kim, and Ji Hyun Kim, and Hyun Hoon Chung, and Hak Jae Kim, and Yong Beom Kim, and Jae Weon Kim, and Noh Hyun Park, and Yong Sang Song, and Soon-Beom Kang
January 2017, The journal of obstetrics and gynaecology research,
Hee Seung Kim, and Ji Hyun Kim, and Hyun Hoon Chung, and Hak Jae Kim, and Yong Beom Kim, and Jae Weon Kim, and Noh Hyun Park, and Yong Sang Song, and Soon-Beom Kang
January 2020, Frontiers in oncology,
Hee Seung Kim, and Ji Hyun Kim, and Hyun Hoon Chung, and Hak Jae Kim, and Yong Beom Kim, and Jae Weon Kim, and Noh Hyun Park, and Yong Sang Song, and Soon-Beom Kang
October 2012, European journal of cancer (Oxford, England : 1990),
Hee Seung Kim, and Ji Hyun Kim, and Hyun Hoon Chung, and Hak Jae Kim, and Yong Beom Kim, and Jae Weon Kim, and Noh Hyun Park, and Yong Sang Song, and Soon-Beom Kang
March 2011, Zhonghua bing li xue za zhi = Chinese journal of pathology,
Hee Seung Kim, and Ji Hyun Kim, and Hyun Hoon Chung, and Hak Jae Kim, and Yong Beom Kim, and Jae Weon Kim, and Noh Hyun Park, and Yong Sang Song, and Soon-Beom Kang
January 2020, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
Hee Seung Kim, and Ji Hyun Kim, and Hyun Hoon Chung, and Hak Jae Kim, and Yong Beom Kim, and Jae Weon Kim, and Noh Hyun Park, and Yong Sang Song, and Soon-Beom Kang
July 2013, Journal of gynecologic oncology,
Copied contents to your clipboard!